 James Burton
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 33 | 2025 | 831 | 3.750 |
Why?
| | Hepatitis C | 17 | 2021 | 238 | 2.600 |
Why?
| | Antiviral Agents | 17 | 2021 | 712 | 2.150 |
Why?
| | Hepatitis C, Chronic | 11 | 2021 | 153 | 2.130 |
Why?
| | Ribavirin | 8 | 2015 | 91 | 1.450 |
Why?
| | Hepacivirus | 11 | 2021 | 235 | 0.900 |
Why?
| | Protease Inhibitors | 3 | 2018 | 106 | 0.870 |
Why?
| | Proline | 6 | 2015 | 76 | 0.870 |
Why?
| | Kidney Transplantation | 4 | 2023 | 670 | 0.780 |
Why?
| | Liver Function Tests | 3 | 2022 | 111 | 0.770 |
Why?
| | Liver | 11 | 2023 | 1838 | 0.730 |
Why?
| | Oligopeptides | 5 | 2015 | 256 | 0.700 |
Why?
| | Interferon-alpha | 3 | 2014 | 194 | 0.690 |
Why?
| | Drug Therapy, Combination | 12 | 2018 | 1037 | 0.660 |
Why?
| | Liver Failure | 4 | 2016 | 91 | 0.650 |
Why?
| | Patient Selection | 3 | 2020 | 662 | 0.630 |
Why?
| | Polyethylene Glycols | 4 | 2014 | 601 | 0.610 |
Why?
| | Interferons | 4 | 2015 | 194 | 0.580 |
Why?
| | Living Donors | 7 | 2022 | 287 | 0.550 |
Why?
| | Graft Rejection | 4 | 2018 | 597 | 0.540 |
Why?
| | Recurrence | 12 | 2015 | 1005 | 0.480 |
Why?
| | Postoperative Complications | 5 | 2022 | 2476 | 0.440 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2022 | 260 | 0.390 |
Why?
| | Colonoscopy | 2 | 2024 | 235 | 0.360 |
Why?
| | Immunocompromised Host | 1 | 2013 | 197 | 0.360 |
Why?
| | Viral Nonstructural Proteins | 2 | 2014 | 58 | 0.340 |
Why?
| | Humans | 77 | 2025 | 129212 | 0.330 |
Why?
| | Graft Survival | 4 | 2023 | 511 | 0.320 |
Why?
| | Middle Aged | 37 | 2024 | 31075 | 0.310 |
Why?
| | Home Care Services, Hospital-Based | 2 | 1999 | 10 | 0.310 |
Why?
| | Tissue Donors | 4 | 2021 | 391 | 0.310 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 375 | 0.300 |
Why?
| | Decision Support Techniques | 2 | 2018 | 395 | 0.280 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.270 |
Why?
| | Esophageal and Gastric Varices | 1 | 2007 | 37 | 0.270 |
Why?
| | Acute Disease | 7 | 2008 | 977 | 0.270 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2736 | 0.260 |
Why?
| | Tissue and Organ Procurement | 2 | 2023 | 288 | 0.250 |
Why?
| | Health Services for the Aged | 5 | 2000 | 72 | 0.250 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 280 | 0.240 |
Why?
| | Reproducibility of Results | 5 | 2022 | 3067 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1056 | 0.230 |
Why?
| | Cholates | 2 | 2022 | 2 | 0.230 |
Why?
| | Geriatrics | 7 | 2000 | 80 | 0.230 |
Why?
| | Health Care Rationing | 1 | 2004 | 57 | 0.220 |
Why?
| | Male | 42 | 2024 | 63491 | 0.220 |
Why?
| | United States | 17 | 2023 | 13873 | 0.220 |
Why?
| | Solitary Kidney | 1 | 2023 | 5 | 0.220 |
Why?
| | Aged | 30 | 2024 | 22030 | 0.220 |
Why?
| | Home Care Services | 3 | 1997 | 244 | 0.220 |
Why?
| | Viremia | 3 | 2021 | 131 | 0.220 |
Why?
| | Cecal Neoplasms | 1 | 2003 | 1 | 0.210 |
Why?
| | Jejunoileal Bypass | 1 | 2003 | 1 | 0.210 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 87 | 0.210 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1834 | 0.210 |
Why?
| | Liver Diseases | 1 | 2006 | 288 | 0.210 |
Why?
| | Female | 41 | 2024 | 68600 | 0.210 |
Why?
| | Reoperation | 4 | 2007 | 543 | 0.210 |
Why?
| | Treatment Outcome | 15 | 2022 | 10189 | 0.210 |
Why?
| | Colonic Polyps | 1 | 2024 | 87 | 0.200 |
Why?
| | Mushroom Poisoning | 1 | 2002 | 6 | 0.200 |
Why?
| | Cholangitis | 1 | 2022 | 20 | 0.190 |
Why?
| | Transplant Recipients | 2 | 2021 | 160 | 0.190 |
Why?
| | Forecasting | 3 | 2014 | 358 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1303 | 0.180 |
Why?
| | Cholangitis, Sclerosing | 1 | 2022 | 71 | 0.180 |
Why?
| | Liver Circulation | 1 | 2021 | 19 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 245 | 0.180 |
Why?
| | Adult | 22 | 2024 | 35464 | 0.180 |
Why?
| | Famous Persons | 1 | 2000 | 7 | 0.170 |
Why?
| | Nursing Homes | 2 | 1994 | 159 | 0.170 |
Why?
| | Deuterium | 1 | 2021 | 87 | 0.170 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 751 | 0.170 |
Why?
| | Carbon Isotopes | 1 | 2021 | 125 | 0.170 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 27 | 0.170 |
Why?
| | Healthy Volunteers | 1 | 2021 | 199 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 167 | 0.170 |
Why?
| | Sofosbuvir | 2 | 2021 | 58 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2025 | 640 | 0.160 |
Why?
| | Donor Selection | 1 | 2020 | 75 | 0.160 |
Why?
| | Allografts | 1 | 2020 | 136 | 0.160 |
Why?
| | Carbamates | 2 | 2021 | 46 | 0.160 |
Why?
| | Reference Values | 1 | 2021 | 793 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 101 | 0.160 |
Why?
| | Kidney | 3 | 2023 | 1375 | 0.160 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 20 | 0.150 |
Why?
| | Biopsy | 2 | 2020 | 1087 | 0.150 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 678 | 0.150 |
Why?
| | Practice Patterns, Physicians' | 2 | 2005 | 1264 | 0.150 |
Why?
| | Cohort Studies | 6 | 2018 | 5408 | 0.150 |
Why?
| | RNA, Viral | 4 | 2015 | 619 | 0.140 |
Why?
| | Geriatric Assessment | 2 | 1997 | 205 | 0.140 |
Why?
| | Coronary Angiography | 3 | 2020 | 306 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 31 | 0.140 |
Why?
| | Prospective Studies | 8 | 2024 | 7103 | 0.140 |
Why?
| | Physician-Patient Relations | 3 | 2000 | 537 | 0.140 |
Why?
| | Eligibility Determination | 2 | 1997 | 63 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2018 | 325 | 0.140 |
Why?
| | Thrombolytic Therapy | 2 | 1997 | 137 | 0.140 |
Why?
| | Drug Interactions | 3 | 2013 | 390 | 0.140 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 185 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 102 | 0.140 |
Why?
| | Consensus | 1 | 2020 | 612 | 0.130 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 69 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 78 | 0.130 |
Why?
| | Family Planning Policy | 1 | 2016 | 1 | 0.130 |
Why?
| | Retrospective Studies | 11 | 2022 | 14488 | 0.130 |
Why?
| | Odds Ratio | 4 | 2015 | 1023 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2003 | 895 | 0.130 |
Why?
| | Health Planning | 1 | 2016 | 47 | 0.130 |
Why?
| | Public Policy | 1 | 2016 | 67 | 0.130 |
Why?
| | Long-Term Care | 1 | 2016 | 91 | 0.120 |
Why?
| | Population Dynamics | 1 | 2016 | 136 | 0.120 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 46 | 0.120 |
Why?
| | Prognosis | 5 | 2020 | 3791 | 0.120 |
Why?
| | Fibrosis | 1 | 2018 | 520 | 0.120 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 9 | 0.120 |
Why?
| | Time Factors | 10 | 2018 | 6549 | 0.120 |
Why?
| | Genotype | 3 | 2015 | 1839 | 0.120 |
Why?
| | Program Evaluation | 1 | 1999 | 873 | 0.120 |
Why?
| | Survival Analysis | 4 | 2018 | 1271 | 0.110 |
Why?
| | Anilides | 1 | 2014 | 73 | 0.110 |
Why?
| | Comprehensive Health Care | 1 | 1994 | 21 | 0.110 |
Why?
| | Homes for the Aged | 1 | 1994 | 27 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 286 | 0.110 |
Why?
| | Young Adult | 7 | 2021 | 12396 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2018 | 574 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 121 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 1998 | 628 | 0.110 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2013 | 43 | 0.100 |
Why?
| | Factor Xa Inhibitors | 2 | 2005 | 170 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 30 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 218 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2016 | 4886 | 0.100 |
Why?
| | Spinal Diseases | 1 | 1993 | 48 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 53 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1500 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 65 | 0.100 |
Why?
| | Myocardial Infarction | 3 | 2005 | 1019 | 0.100 |
Why?
| | Quality of Life | 4 | 2018 | 2693 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2012 | 65 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 685 | 0.090 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 77 | 0.090 |
Why?
| | Postoperative Care | 1 | 2013 | 238 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 241 | 0.090 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 99 | 0.090 |
Why?
| | Hepatic Insufficiency | 1 | 2010 | 4 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 840 | 0.090 |
Why?
| | Preoperative Care | 1 | 2013 | 336 | 0.090 |
Why?
| | Th1 Cells | 2 | 2008 | 138 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 210 | 0.090 |
Why?
| | Blood Component Transfusion | 1 | 2011 | 82 | 0.090 |
Why?
| | Death Certificates | 1 | 1990 | 30 | 0.080 |
Why?
| | Autopsy | 1 | 1990 | 94 | 0.080 |
Why?
| | Nucleosides | 1 | 2009 | 27 | 0.080 |
Why?
| | Aged, 80 and over | 9 | 2015 | 7061 | 0.080 |
Why?
| | Myocardial Stunning | 1 | 2009 | 5 | 0.080 |
Why?
| | Uremia | 1 | 2009 | 14 | 0.080 |
Why?
| | Primary Health Care | 2 | 1993 | 1678 | 0.080 |
Why?
| | Longitudinal Studies | 4 | 2016 | 2713 | 0.080 |
Why?
| | Prodrugs | 1 | 2009 | 48 | 0.080 |
Why?
| | Erythrocyte Transfusion | 1 | 2011 | 181 | 0.080 |
Why?
| | Cross Infection | 1 | 2011 | 216 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2009 | 110 | 0.080 |
Why?
| | RNA | 1 | 2015 | 883 | 0.080 |
Why?
| | Drug Discovery | 1 | 2009 | 131 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 675 | 0.070 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1988 | 78 | 0.070 |
Why?
| | Thrombelastography | 2 | 2022 | 150 | 0.070 |
Why?
| | Urinary Incontinence | 1 | 1988 | 62 | 0.070 |
Why?
| | Registries | 1 | 2016 | 1886 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2008 | 769 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 278 | 0.070 |
Why?
| | Risk Factors | 8 | 2020 | 9747 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1944 | 0.070 |
Why?
| | Patient Readmission | 2 | 2010 | 664 | 0.070 |
Why?
| | Propionates | 2 | 2005 | 36 | 0.070 |
Why?
| | Platelet Count | 1 | 2007 | 82 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2007 | 138 | 0.070 |
Why?
| | Naphthalenes | 2 | 2005 | 57 | 0.070 |
Why?
| | Ventricular Function, Left | 2 | 2009 | 526 | 0.070 |
Why?
| | Biomarkers | 2 | 2015 | 3968 | 0.070 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2006 | 12 | 0.070 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 27 | 0.070 |
Why?
| | Models, Statistical | 2 | 2015 | 622 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 448 | 0.070 |
Why?
| | Behavior Therapy | 1 | 1988 | 238 | 0.060 |
Why?
| | ROC Curve | 1 | 2007 | 503 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 1983 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2071 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 423 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1201 | 0.060 |
Why?
| | Heparin | 4 | 2005 | 253 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1004 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 515 | 0.060 |
Why?
| | Ambulatory Care | 1 | 1988 | 504 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2005 | 118 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 339 | 0.060 |
Why?
| | Skilled Nursing Facilities | 1 | 1985 | 131 | 0.060 |
Why?
| | Incidence | 2 | 2010 | 2638 | 0.060 |
Why?
| | House Calls | 1 | 1985 | 123 | 0.050 |
Why?
| | Hepatitis B Antibodies | 1 | 2003 | 11 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2006 | 272 | 0.050 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2003 | 14 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2003 | 35 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 547 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2005 | 558 | 0.050 |
Why?
| | Continuity of Patient Care | 1 | 1985 | 275 | 0.050 |
Why?
| | Pilot Projects | 3 | 2009 | 1584 | 0.050 |
Why?
| | Risk Assessment | 4 | 2015 | 3234 | 0.050 |
Why?
| | Aging | 1 | 1993 | 1774 | 0.050 |
Why?
| | Colectomy | 1 | 2003 | 94 | 0.050 |
Why?
| | Length of Stay | 3 | 2011 | 1121 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Adenoma | 1 | 2024 | 212 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 27 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2003 | 254 | 0.050 |
Why?
| | Plasma | 2 | 2014 | 206 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2002 | 300 | 0.050 |
Why?
| | DNA, Viral | 1 | 2003 | 349 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 19 | 0.040 |
Why?
| | Sustained Virologic Response | 1 | 2021 | 37 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 68 | 0.040 |
Why?
| | Critical Care | 1 | 1985 | 551 | 0.040 |
Why?
| | Health Planning Councils | 1 | 2000 | 6 | 0.040 |
Why?
| | Government | 1 | 2000 | 12 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2006 | 856 | 0.040 |
Why?
| | Thrombosis | 1 | 2004 | 343 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2022 | 238 | 0.040 |
Why?
| | Mental Disorders | 1 | 1988 | 1029 | 0.040 |
Why?
| | Referral and Consultation | 1 | 1985 | 731 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2000 | 71 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2004 | 864 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 206 | 0.040 |
Why?
| | Baltimore | 1 | 1999 | 45 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 160 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 635 | 0.040 |
Why?
| | Specialization | 1 | 2000 | 145 | 0.040 |
Why?
| | History, 20th Century | 1 | 2000 | 290 | 0.040 |
Why?
| | Adolescent | 6 | 2015 | 20371 | 0.040 |
Why?
| | Hospitals, University | 1 | 1999 | 178 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 767 | 0.040 |
Why?
| | Streptokinase | 2 | 1997 | 10 | 0.040 |
Why?
| | General Surgery | 1 | 2000 | 152 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 327 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2004 | 498 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 818 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2018 | 70 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 27 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 1997 | 28 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 182 | 0.040 |
Why?
| | Osteoporosis | 1 | 2000 | 232 | 0.030 |
Why?
| | Safety | 1 | 1999 | 330 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 304 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1010 | 0.030 |
Why?
| | Cause of Death | 2 | 2007 | 392 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 2 | 1997 | 221 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 158 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 649 | 0.030 |
Why?
| | Attitude | 1 | 1998 | 251 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 373 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1997 | 123 | 0.030 |
Why?
| | China | 1 | 2016 | 191 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 317 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 342 | 0.030 |
Why?
| | Phlebotomy | 1 | 2015 | 18 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Population | 1 | 2015 | 33 | 0.030 |
Why?
| | Family Characteristics | 1 | 2016 | 179 | 0.030 |
Why?
| | Uracil | 1 | 2014 | 30 | 0.030 |
Why?
| | Half-Life | 1 | 2015 | 162 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 481 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 89 | 0.030 |
Why?
| | Biological Assay | 1 | 2015 | 118 | 0.030 |
Why?
| | North America | 1 | 2015 | 290 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 68 | 0.030 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 49 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 173 | 0.030 |
Why?
| | Valine | 1 | 2014 | 81 | 0.030 |
Why?
| | Cadaver | 1 | 2015 | 306 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 73 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 257 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2015 | 732 | 0.030 |
Why?
| | Frail Elderly | 1 | 1994 | 121 | 0.030 |
Why?
| | Hepatocytes | 1 | 2014 | 216 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 370 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 303 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3372 | 0.030 |
Why?
| | Cholestasis | 1 | 2015 | 232 | 0.020 |
Why?
| | Neutrophils | 1 | 2018 | 1202 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 172 | 0.020 |
Why?
| | Medicare Part B | 1 | 1991 | 3 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 758 | 0.020 |
Why?
| | HIV-1 | 1 | 2018 | 836 | 0.020 |
Why?
| | Pain | 1 | 2018 | 770 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 216 | 0.020 |
Why?
| | Physical Examination | 1 | 1993 | 235 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 766 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2559 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 535 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1993 | 231 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 496 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 415 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 959 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1991 | 94 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 1992 | 264 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1997 | 721 | 0.020 |
Why?
| | Body Weight | 1 | 2015 | 938 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 521 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 1998 | 1093 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1710 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1038 | 0.020 |
Why?
| | Anti-Retroviral Agents | 1 | 2012 | 231 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2003 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 515 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 382 | 0.020 |
Why?
| | Erythrocytes | 1 | 2015 | 672 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 459 | 0.020 |
Why?
| | Anemia, Pernicious | 1 | 1988 | 9 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1302 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2876 | 0.020 |
Why?
| | Urinary Incontinence, Stress | 1 | 1988 | 14 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1993 | 1424 | 0.020 |
Why?
| | Fibrinogens, Abnormal | 1 | 2008 | 4 | 0.020 |
Why?
| | Biofeedback, Psychology | 1 | 1988 | 35 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1705 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 1988 | 122 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2010 | 480 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 82 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2009 | 335 | 0.020 |
Why?
| | Societies, Medical | 1 | 1991 | 747 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2007 | 73 | 0.020 |
Why?
| | Child | 2 | 2021 | 20853 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 154 | 0.020 |
Why?
| | Hospitalization | 1 | 1996 | 2069 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2011 | 850 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 1988 | 127 | 0.020 |
Why?
| | Organizational Affiliation | 1 | 1985 | 8 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 264 | 0.020 |
Why?
| | Internal Medicine | 1 | 1988 | 246 | 0.020 |
Why?
| | Stroke Volume | 1 | 2009 | 590 | 0.020 |
Why?
| | Pressure Ulcer | 1 | 1985 | 34 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1985 | 201 | 0.020 |
Why?
| | Waiting Lists | 1 | 2007 | 237 | 0.020 |
Why?
| | Dementia | 1 | 1988 | 227 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 713 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5057 | 0.010 |
Why?
| | Partial Thromboplastin Time | 1 | 2005 | 52 | 0.010 |
Why?
| | Fluid Therapy | 1 | 1985 | 134 | 0.010 |
Why?
| | Epitopes | 1 | 2006 | 469 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 845 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2006 | 349 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2281 | 0.010 |
Why?
| | Pneumonia | 1 | 1990 | 613 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2004 | 45 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 45 | 0.010 |
Why?
| | Canada | 2 | 1997 | 347 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2004 | 60 | 0.010 |
Why?
| | Physician's Role | 1 | 1985 | 206 | 0.010 |
Why?
| | HIV Infections | 1 | 2018 | 2719 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2006 | 1156 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2004 | 216 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5387 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1727 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 606 | 0.010 |
Why?
| | Ischemia | 1 | 2005 | 406 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1360 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4412 | 0.010 |
Why?
| | Hemorrhage | 1 | 2005 | 677 | 0.010 |
Why?
| | Foundations | 1 | 2000 | 24 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2000 | 73 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1985 | 737 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1718 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 3074 | 0.010 |
Why?
| | Education, Medical | 1 | 2000 | 243 | 0.010 |
Why?
| | Vascular Patency | 1 | 1997 | 102 | 0.010 |
Why?
| | Coronary Circulation | 1 | 1997 | 138 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 10507 | 0.010 |
Why?
| | Regression Analysis | 1 | 1997 | 993 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 717 | 0.010 |
Why?
| | Institutionalization | 1 | 1992 | 12 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1874 | 0.010 |
Why?
| | Organizational Policy | 1 | 1991 | 77 | 0.010 |
Why?
| | Sex Factors | 1 | 1997 | 1961 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|